Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

NCT07441876 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: BMN 333
DRUG: Vosoritide Injection [Voxzogo]

Sponsor

BioMarin Pharmaceutical